A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction.
Background: Heart failure is a leading cause of death worldwide. Cyclic nucleotide phosphodiesterases (PDEs), through degradation of cyclic nucleotides, play critical roles in cardiovascular biology and disease. Our preliminary screening studies have revealed PDE10A upregulation in the diseased heart. However, the role of PDE10A in cardiovascular biology and disease are largely uncharacterized. The current study is aimed to investigate the regulation and function of PDE10A in cardiac cells and in the progression of cardiac remodeling and dysfunction. Methods: We used isolated adult mouse cardiac myocytes (CMs) and fibroblasts (CFs), as well as preclinical mouse models of hypertrophy and/or heart failure. The PDE10A selective inhibitor TP-10, and global PDE10A knock out mice (PDE10A-KO) were used. Results: We found that PDE10A expression remains relatively low in normal and exercised heart tissues. However, PDE10A is significantly upregulated in mouse and human failing hearts. In vitro, PDE10A deficiency or inhibiting PDE10A with selective inhibitor TP-10, attenuated CM pathological hypertrophy induced by Angiotensin II (Ang II), phenylephrine (PE), and isoproterenol (ISO), but did not affect CM physiological hypertrophy induced by insulin-like growth factor 1 (IGF-1). TP-10 also reduced transforming growth factor-β (TGF-β)-stimulated CF activation, proliferation, migration and ECM synthesis. TP-10 treatment elevated both cAMP and cGMP levels in CM and CF, consistent with PDE10A as a cAMP/cGMP dual-specific PDE. In vivo, global PDE10A deficiency significantly attenuated myocardial hypertrophy, cardiac fibrosis, and/or dysfunction induced by chronic pressure overload via thoracic aorta constriction (TAC) or chronic neurohormonal stimulation via Ang II infusion. Importantly, we demonstrated that the pharmacological effect of TP-10 is specifically through PDE10A inhibition. In addition, TP-10 is able to reverse pre-established cardiac hypertrophy and dysfunction. RNA-Sequencing and bioinformatics analysis further identified a PDE10A-regualted transcriptome involved in cardiac hypertrophy, fibrosis, and cardiomyopathy. Conclusions: Taken together, our study elucidates a novel role for PDE10A in the regulation of pathological cardiac remodeling and development of heart failure. Given that PDE10A has been proven to be a safe drug target, PDE10A inhibition may represent a novel therapeutic strategy for preventing and treating cardiac diseases associated with cardiac remodeling.